Panelist: Orlando Serani Program Lead Advanced Cellular Therapies Supply Chain Johnson & Johnson
Panelist: Dr. David Rhew Chief Medical Officer & VP Healthcare Microsoft
Panelist: Ariette van Strien President Marken, a UPS Healthcare company
Panelist: Joerg Ahlgrimm President and Chief Operating Officer Center for Breakthrough Medicines
Moderator: Adlai Goldberg Global Digital, Social and Commercial Innovation Life Sciences Leader EY
There are more than 2,600 C> clinical trials in different modalities at different stages of maturity worldwide signalling a potential wave of 300 to 400 product approvals between 2022 and 2027. That means the groundwork for seamless cell and gene therapy care delivery needs to be laid now. There are many stakeholders involved in the complex C> treatment journey requiring Pharma to develop a collaborative plan, prepare a skilled workforce, and be ready to scale up rapidly.
C>s require a radically new delivery approach to that which we are traditionally familiar with. A complex balancing act of multi-stakeholder processes hinge on treatment advances, product availability, and the network’s ability to meet demand. And that’s before we think about scaling the delivery to more than a few thousand patients.
This webinar will bring together experts in developing cell and gene therapy manufacturing models and interconnected supply networks, as well as delivering an excellent patient experience throughout their treatment journey. Learn from the best about how you can: